新型降糖药物与帕金森病风险关联的Meta分析
Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.
作者信息
Tang Huilin, Lu Ying, Okun Michael S, Donahoo William T, Ramirez-Zamora Adolfo, Wang Fei, Huang Yu, Chen Wei-Han, Virnig Beth A, Bian Jiang, Guo Jingchuan
机构信息
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.
出版信息
Mov Disord Clin Pract. 2023 Oct 13;10(11):1659-1665. doi: 10.1002/mdc3.13893. eCollection 2023 Nov.
BACKGROUND
The association between newer classes of glucose-lowering drugs (GLDs) and the risk of Parkinson's disease (PD) remains unclear.
OBJECTIVE
The aim was to examine the effect of newer GLDs on the risk of PD through a meta-analysis of randomized outcome trials.
METHODS
The methods included randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto's method.
RESULTS
The study included 24 trials involving 33 PD cases among 185,305 participants during a median follow-up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR: 0.50; 95% CI: 0.25-0.98) than placebo.
CONCLUSION
Newer GLDs may possibly be associated with a decreased risk of PD; however, larger datasets are required to confirm or refute this notion.
背景
新型降糖药物（GLDs）与帕金森病（PD）风险之间的关联尚不清楚。
目的
通过对随机结局试验进行荟萃分析，研究新型GLDs对PD风险的影响。
方法
方法包括随机安慰剂对照结局试验，这些试验报告了在有或没有2型糖尿病的参与者中，与三类新型GLDs（即二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白-2抑制剂）相关的PD事件。使用Peto方法估计合并比值比（OR）和95%置信区间（CI）。
结果
该研究纳入了24项试验，在185305名参与者中，经过中位数为2.2年的随访，有33例PD病例。与安慰剂相比，新型GLDs与较低的PD风险显著相关（OR：0.50；95%CI：0.25-0.98）。
结论
新型GLDs可能与降低PD风险有关；然而，需要更大的数据集来证实或反驳这一观点。
Zotero 插件